ArticleNature communications2026
Early and late RNA eQTL are driven by different genetic mechanisms.
Saori Sakaue, Accelerating Medicines Partnership®: RA/SLE Network, Soumya Raychaudhuri
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
3 authors.
Accelerating Medicines Partnership®: RA/SLE Network
Funding
PEARL: Pathway Exploration and Analysis in Renal LupusUH2AR067688 · NIAMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI DIAMOND, BETTY, WOFSY, DAVID · 2014 to 2020
$9.0MTissue Acquisition Research GroupUM2AR067678 · NIAMS · STANFORD UNIVERSITY · PI HOLERS, VERNON MICHAEL, UTZ, PAUL JOSEPH · 2014 to 2020
$8.2MMulti-Ethnic Translational Research Optimization (METRO) Lupus ConsortiumUH2AR067689 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BUYON, JILL P, PUTTERMAN, CHAIM · 2014 to 2020
$6.3MEvolving Adaptive and Effector Mechanisms from Pre-RA Through Established DiseaseUH2AR067681 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI HOLERS, VERNON MICHAEL · 2014 to 2020
$5.5MDiscovery and Functional Impact of Common and Rare Variants in RAR01AR063759 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Soumya Raychaudhuri · 2013 to 2026
$5.4MMolecular and Cellular Dissection of Early Rheumatoid ArthritisUH2AR067694 · NIAMS · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · PI BRENNER, MICHAEL B., GREGERSEN, PETER K. · 2014 to 2020
$5.4MIntegrative analysis of high dimensional tissue molecular data to define key biological systems in autoimmune diseases (SBC)UC2AR081023 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Soumya Raychaudhuri · 2022 to 2026
$4.8MRA-SLE Molecular Deconstruction Leadership CenterUH2AR067677 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BRENNER, MICHAEL B., RAYCHAUDHURI, SOUMYA · 2014 to 2020
$4.3MPredicting the impact of genetic variants, genes and pathways on human DiseaseU01HG012009 · NHGRI · BRIGHAM AND WOMEN'S HOSPITAL · PI ALKES L PRICE, Soumya Raychaudhuri · 2021 to 2026
$4.2MCellular Dynamics at the Synovium-Bone interface in RAUH2AR067690 · NIAMS · UNIVERSITY OF ROCHESTER · PI ANOLIK, JENNIFER HOWITT · 2014 to 2020
$3.0MStanford Technology Accelerating Medicines Partnership CenterUH2AR067676 · NIAMS · STANFORD UNIVERSITY · PI ROBINSON, WILLIAM H, UTZ, PAUL JOSEPH · 2014 to 2020
$2.6MAccelerating Medicines Partnership in RA and Lupus: Network Sites (UH2/UH3)UH2AR067679 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2014 to 2020
$2.1MNHGRI NIH HHS U01 HG012009NIAMS NIH HHS R01 AR063759NIAMS NIH HHS UC2 AR081023NIAMS NIH HHS UH2 AR067676NIAMS NIH HHS UH2 AR067677NIAMS NIH HHS UH2 AR067679NIAMS NIH HHS UH2 AR067681NIAMS NIH HHS UH2 AR067685NIAMS NIH HHS UH2 AR067688NIAMS NIH HHS UH2 AR067689NIAMS NIH HHS UH2 AR067690NIAMS NIH HHS UH2 AR067691NIAMS NIH HHS UH2 AR067694NIAMS NIH HHS UM2 AR067678U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01AR063759U.S. Department of Health & Human Services | National Institutes of Health (NIH) U01HG012009U.S. Department of Health & Human Services | National Institutes of Health (NIH) UC2AR081023
6 · The paper itselfAbstract
Understanding the genetic regulation of RNA abundance is essential for defining disease mechanisms. Conventional expression quantitative trait locus (eQTL) studies measure steady-state RNA and capture effects across the entire transcript lifecycle. While most eQTL likely affect transcription by altering promoter or enhancer function within the nucleus, others may act post-transcriptionally through RNA modification or stability in the cytosol. To distinguish these mechanisms, we compare eQTL from mature cellular RNA and recently transcribed nuclear RNA in brain and kidney. We identify distinct causal variants underlying cellular and nuclear eQTL at the same eGenes. Cellular eQTL are enriched in transcribed regions (P = 3.3×10⁻¹²⁶), suggesting post-transcriptional regulation, whereas nuclear eQTL are enriched in distal regulatory elements (P = 7.0×10⁻³²), consistent with transcriptional control. For example, stop-gain variants likely acting through nonsense-mediated decay appear only in cellular eQTL. Conversely, nuclear eQTL variants (e.g., TUBGCP4) within enhancers sometimes uniquely colocalize with disease loci (schizophrenia), revealing distinct regulatory mechanisms.
Indexed as
Gene Expression RegulationQuantitative Trait LociRNAAnimalsBrainHumansKidneyPolymorphism, Single NucleotideSchizophreniaTranscription, GeneticRNA
Identifiers
PMID42034632
PMCPMC13319782
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390